The Use of Radiolabeled Somatostatin Analog Scintigraphy in the Staging of Small Cell Lung Cancer Patients

Abstract

Although 111In-OctreoScan may be used in addition to current SCLC staging methods, there are insufficient data for maintaining that SRS may replace conventional staging.

Brief Report on the Use of Radiolabeled Somatostatin Analogs for the Diagnosis and Treatment of Metastatic Small-Cell Lung Cancer Patients

“…In fact, when ED-SCLC patients are evaluated with 68 Ga-DOTATOC/ DOTATATE PET/CT, we can increase tumor detection rate of conventional SSTR scintigraphy, as already observed for lung cancer patients. 9,10 The use of PET/CT results in similar performances for the primary tumor as compared with Octreoscan (67% versus 78-100%) but shows greater advantage for detection of distant metastasis (37.5-100% versus 26-75%). The identification of liver and brain metastasis were definitively more complicated with a detection rate similar to Octreoscan.…”

Pure small cell carcinoma of the prostate: case report

“…After octreoscan positivity for SCPCa, somatostatin analogs and their radionuclide derivatives might exert a palliative effect in symptomatic patients. [3,10] The prognosis of SCPCa is poor, even in localized and early cases, and the median survival is limited to months. Longterm survivors are rare.…”